longbridgelongbridge
  • Platform Features
    Features
    Investment ProductsPrivate Wealth ManagementTrading ToolsMarket Data ServicesAnalysis ToolsNews ServicesFor Developers
    Account Types
    For IndividualsFor Institutions
  • Café
longbridge
© 2026 Longbridge|Terms of ServicePrivacy Policy

Roche

RHHBY

52.7500.83% ( -0.440 )
Delay Closed: Sep 11, 16:00:00 (EDT)
Start trading
OverviewOverviewOptionsOptionsNewsNewsPostsPostsFinancialsFinancialsForecastForecastValuationValuationShareholdersShareholdersProfileProfile
LongbridgeAI

Current ValuationThe current P/E ratio is 21.75, within the reasonable range, cheaper than 30.7% of the time in the past 5 years, and the industry ranks 37/258, the industry Median -1.28.

21.75xP/E
$52.75Stock price
$2.43Earnings per share
21.75xP/E
Stock price$52.75Earnings per share$2.43

Historical Valuation

P/E ratioTypical rangeMedian
P/E ratio
20.76x
Typical range
18.17x–23.96x

Peer P/E ratio Comparison

It displays how the company's P/E ratio compares to top companies within its industry.
0285684112

The industry median valuation is currently at or below 0 and may not serve as a meaningful benchmark.

Industry P/E ratio Comparison

This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.
0x20x40x60x80x100x
P/E ratio
Name/Symbol
RHHBYUSRoche
21.75x--$336.24B
RHHVFUSROCHE HOLDINGS AG
23.69x--$366.30B
NVSUSNOVARTIS AG
20.44x1.82%$260.70B
AZNUSAstraZeneca
23.78x--$248.41B
SNYUSSanofi
22.30x20.80%$102.48B
SNYNFUSSanofi
22.25x--$102.24B
CHGCYUSChugai Pharmaceutical
22.67x--$68.28B
MKKGYUSMerck
24.07x--$66.22B
RDYUSDr Reddys Laboratories
27.51x9.81%$9.91B
LGNDUSLigand Pharmac-B
28.76x14.55%$5.67B

Risk Warning

Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.